- Home
- MNPR vs FLYX Comparison
MNPR vs FLYX Comparison
Compare MNPR & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNPR | FLYX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.6M | 79.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNPR | FLYX |
|---|---|---|
| Price | $76.19 | $4.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $97.83 | N/A |
| AVG Volume (30 Days) | ★ 163.6K | 15.2K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $362,955,000.00 |
| Revenue This Year | N/A | $28.47 |
| Revenue Next Year | N/A | $22.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.38 |
| 52 Week Low | $21.00 | $1.90 |
| 52 Week High | $105.00 | $6.90 |
Technical Indicators
Market Signals| Indicator | MNPR | FLYX |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 59.08 |
| Support Level | $74.51 | $3.48 |
| Resistance Level | $79.31 | $4.22 |
| Average True Range (ATR) | 6.38 | 0.41 |
| MACD | -0.93 | 0.10 |
| Stochastic Oscillator | 6.10 | 79.66 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.